Research programme: selective androgen receptor modulators - SignalGene
Alternative Names: SARM research programme - SignalGene; Selective androgen receptor modulators research programme - SignalGeneLatest Information Update: 07 Aug 2003
At a glance
- Originator SignalGene [CEASED]
- Class
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Female testosterone deficiency; Hypogonadism; Muscular atrophy
Most Recent Events
- 07 Aug 2003 SignalGene has ceased its pharmaceutical operations
- 07 Aug 2003 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 07 Aug 2003 Discontinued - Preclinical for Female testosterone deficiency in Canada (unspecified route)